Monthly Archives: November 2016

Nucleic Acid Therapeutics: Don’t Hit the Panic Button
November 28, 2016

This blog was written by both Bill Marshall, CEO of MiRagen Therapeutics, and Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. Recent news from Alnylam, Ionis, and Mirna Therapeutics regarding toxicity-related setbacks

Leave a comment

Biotech Venture Capital Mythbusting Redux
November 21, 2016

Venture capital has been on a good run over the past few years across a range of sectors; even with recent slowdown relative to 2014-2015, venture-backed investments remain above historic averages.  In fact, the first three quarters of 2016 alone

1 Comment

Rebooting The Conversation
November 16, 2016

This blog was written by Jason Gardner, founding CEO of Magenta Therapeutics and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. Imagine the conversation today between a patient and doctor on the decision to have a

1 Comment

Option Or Warrant: Alternative Structures For A Future Acquisition
November 15, 2016

This blog was written by Samantha Truex, former CBO of Padlock Therapeutics and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. The search for creative deal structures that strike a “win-win” balance is a noble one.

2 Comments